Robert B. Nadelman, MD; Gary P. Wormser, MD
Disclaimer: The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the New York State Department of Health.
Grant Support: In part by the Tick-borne Diseases Institute of the New York State Department of Health (C-015088).
Requests for Single Reprints: Robert B. Nadelman, MD, New York Medical College, Division of Infectious Diseases, Munger Pavilion, Second Floor, Valhalla, NY 10595.
Current Author Addresses: Drs. Nadelman and Wormser: New York Medical College, Division of Infectious Diseases, Munger Pavilion, Second Floor, Valhalla, NY 10595.
Nadelman R., Wormser G.; Recognition and Treatment of Erythema Migrans: Are We Off Target?. Ann Intern Med. 2002;136:477-479. doi: 10.7326/0003-4819-136-6-200203190-00012
Download citation file:
Published: Ann Intern Med. 2002;136(6):477-479.
The clinical manifestation most closely associated with Lyme disease is the rash that develops at the site of a bite from an Ixodes scapularis tick. Erythema migrans is present in at least 90% of objective cases of Lyme disease (1). Although it usually resolves spontaneously (that is, without any antimicrobial therapy), it may be the forerunner, in untreated patients, of cardiac, neurologic, or arthritic conditions, causing significant morbidity (1, 2). These sequelae generally respond to antibiotics (1-3). However, treatment of patients with erythema migrans is usually highly effective in preventing the development of these complications (1-3).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Infectious Disease, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only